Preliminary results of surufatinib (Suru) plus standard chemotherapy (ChT) as second line (2L) treatment of advanced gastric cancer (aGC): A single-arm, phase 2 clinical trial.

被引：0

作者：

Han, Ting ^{[1
]}

Lin, Xiaolin ^{[1
]}

Zhuo, Meng ^{[1
]}

Jiao, Feng ^{[1
]}

Cui, Jiujie ^{[1
]}

Qiu, Xiaoxia ^{[1
]}

Xiao, Xiuying ^{[1
]}

机构：

[1] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Oncol, Shanghai, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期

关键词：

D O I：

10.1200/JCO.2024.42.3_suppl.353

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：353 / 353

页数：1

共 50 条

[1] Lenvatinib plus toripalimab as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-arm, phase 2 trial.
Jian, Zhou
Fan, Jia
Shi, Guo-Ming
Huang, Xiao-Yong
Wu, Dong
Liang, Fei
Yang, Guo-Huan
Lu, Jia-Cheng
Chen, Yi
Ge, Ning-Ling
Ji, Yuan
Hou, Y. Y.
Sun, Hui-Chuan
Qiu, Shuang-Jian
Ye, Qing-Hai
Huang, Xiao-Wu
Shi, Ying-Hong
Gao, Qiang
Yang, Xin-Rong
Wang, Xiao-Ying
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[2] A multicenter, single-arm, phase 2 study of surufatinib plus toripalimab for patients with advanced endometrial cancer
Yuan, Guangwen
Li, Zhiping
Ye, Feng
Zhang, Bingzhong
Shen, Lin
Zhang, Yan-Qiao
Yu, Xianjun
Cheng, Ying
Liu, Baorui
Wang, Jianliu
Chen, Xiaojun
Zhou, Jinghong
Shi, Haiyan
Tan, Panfeng
Fan, Songhua
Shi, Michael
Su, Weiguo
Wu, Lingying
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[3] Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial
Le Zhang
Weixue Wang
Shaohua Ge
Hongli Li
Ming Bai
Jingjing Duan
Yuchong Yang
Tao Ning
Rui Liu
Xia Wang
Zhi Ji
Feixue Wang
Haiyang Zhang
Yi Ba
Ting Deng
BMC Cancer, 23
[4] Cambrelizumab plus chemotherapy as conversion therapy for unresectable metastatic gastric cancer: A single-arm, multicenter, prospective clinical trial.
Li, Shuang
He, Liang
Li, Meng
Wang, Quan
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16032 - E16032
[5] Perioperative penpulimab plus anlotinib combined with chemotherapy for locally advanced gastric cancer: A single arm, multicenter, phase II clinical trial.
Wang, Mian
Zhou, Wei
Miao, Yan
Tan, Zhaobang
Li, Yiding
Hong, Liu
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS485 - TPS485
[6] Sintilimab Plus Apatinib and Chemotherapy as Second-/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial
Zhang, Le
Wang, Weixue
Ge, Shaohua
Li, Hongli
Bai, Ming
Duan, Jingjing
Yang, Yuchong
Ning, Tao
Liu, Rui
Wang, Xia
Ji, Zhi
Wang, Feixue
Zhang, Haiyang
Ba, Yi
Deng, Ting
BMC CANCER, 2023, 23 (01)
[7] Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial
Colombo, N.
McMeekin, D. S.
Schwartz, P. E.
Sessa, C.
Gehrig, P. A.
Holloway, R.
Braly, P.
Matei, D.
Morosky, A.
Dodion, P. F.
Einstein, M. H.
Haluska, F.
BRITISH JOURNAL OF CANCER, 2013, 108 (05) : 1021 - 1026
[8] Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial
N Colombo
D S McMeekin
P E Schwartz
C Sessa
P A Gehrig
R Holloway
P Braly
D Matei
A Morosky
P F Dodion
M H Einstein
F Haluska
British Journal of Cancer, 2013, 108 : 1021 - 1026
[9] Anlotinib combined with mXELIRI as second-line treatment in advanced colorectal cancer pretreated with bevacizumab plus standard chemotherapy: A single-arm, phase IB/II study
Qu, Xin
Chen, Xian
Li, Yong
Liu, Li-rong
Qu, Yan-chun
Hou, Fang-fang
Li, Wen-zhu
Liu, Yi-hong
Zhu, Yan-juan
Zhang, Haibo
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[10] Surufatinib plus sintilimab in patients with advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A single-arm, open-label, single-center phase II trial.
Zhang, Dong-Sheng
Liu, Fu-Rong
Lu, Yun-Xin
Bai, Bing
Zhang, Yang
Wang, Zhi-Qiang
Liu, Yu
Chen, Jian-Wen
Wang, Feng
Xu, Rui-Hua
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 358 - 358

← 1 2 3 4 5 →